In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Entomed SA

Investing in French Biotech--When It's Not Too French

Neuro 3d's €31.5 million third round late in 2004 was one of France's largest private biotech financings for years. But none of the investors are looking to France to provide the exit opportunities, which are more likely to be found in M&A, or in Switzerland.

BioPharmaceutical Business Strategies

Investing in French Biotech--When It's Not Too French

Neuro 3d's €31.5 million third round late in 2004 was one of France's largest private biotech financings for years. But none of the investors are looking to France to provide the exit opportunities, which are more likely to be found in M&A, or in Switzerland.

BioPharmaceutical Business Strategies

Recent Dealmaking (05/2003)

Summarizing the month in European dealmaking.

Entomed SA

"Insects represent three times the biodiversity of plants and microorganisms put together, " says Mario Thomas, PhD, CEO of Entomed SA. That's why Entomed is hopeful that insect genes will help it discover novel anti-infectives and other drugs.

BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register